Introduction {#sec1-1}
============

Nasopharyngeal carcinoma (NPC) is regarded as the most common epithelial tumor of the head and neck in Southeast Asia, especially in South China (Wei and Sham, 2005). With intensity-modulated radiation therapy combined with chemotherapy, the 5-year estimated local recurrence-free rate for patients with NPC exceeds 90% (Lee et al., 2014; Lin et al., 2014; Sun et al., 2014). However, the 5-year overall survival rate is only around 80%, and distant metastases have become the primary reason for treatment failure (Lee et al., 2014; Lin et al., 2014; Sun et al., 2014; Wang et al., 2014; Zong et al., 2015). Therefore, there is an urgent need to find additional effective therapeutic modalities. Determining ways to further decrease the risk of distant metastases is a hot topic in the current treatment of NPC, and immunotherapy might be a novel treatment for cancer.

Human natural killer (NK) cells, a type of lymphoid cells, play an integral role in innate immunity to resist against infections and tumors by their cytotoxic activity (Pardoll, 2001). The cytotoxicity of NK cells is usually involved by the regulation of both the activating and inhibitory surface reporters. Natural cytotoxicity receptors (NCRs), such as NKp30, NKp44, and NKp46, as well as NK group 2, member D (NKG2D) are representative activating receptors that could be combined with their corresponding ligands to trigger the activity of NK cells (Pardoll, 2001; Koch et al., 2013). However, inhibitory receptors such as CD158b and CD159a can confer inhibitory signals to NK cells by immunoreceptor tyrosine-based inhibition motifs to reduce the cytotoxicity of NK cells (Konjevic et al., 2009). When major histocompatibility complex-I expression on tumor cells is low or absent, tumor cells will be identified by NK cells, and their activating receptors will play major roles to enhance the cytotoxicity (Zheng et al., 2006). In addition, NKG2D is expressed on the membranes of NKT cells, CD8+ T cells, γδ T cells, and particular subsets of CD4+ T cells and binds to distinct ligands of tumors to play an increasingly important role in both innate and adaptive immunity (Raulet et al., 2013). Hence, NK cell receptors and NKG2D-mediated immunotherapy may be a powerful avenue for the treatment of cancer.

At present, increasing research on both NK cell surface receptors and NKG2D in cervical cancer, acute myelocytic leukemia, and viral infections have demonstrated the positive correlation between the downregulated killing effects of NK cells and the low expression of NCRs or NKG2D (De Maria et al., 2003; Garcia-Iglesias et al., 2009). In addition, the negative correlation between inhibitory receptors of NK cells and tumor progression has been revealed (Konjevic et al., 2009). Furthermore, the alteration of NKG2D on certain T lymphocytes has been proven to correlate closely with immunosuppression in the host (Clayton et al., 2008). However, the expression of representative receptors on NK cells and NKG2D on immunocytes in patients with NPC has not been well investigated. Thus, there is a pressing need to investigate the possibly aberrant expression of these receptors to provide a new pathway for tumor immune evasion and to explore a novel immunotherapeutic intervention for patients with NPC.

Therefore, the aim of this study was to investigate the expression of receptors on NK cells and NKG2D on immunocytes by flow cytometry in the peripheral blood of patients with NPC as compared with that of healthy controls in order to provide a reference for the clinical management of NPC.

Materials and methods {#sec1-2}
=====================

Patients {#sec2-1}
--------

The study group consisted of 64 newly diagnosed and previously untreated patients with NPC. The clinical data of the patients referred to Fujian Provincial Cancer Hospital between June 2015 and November 2015 were reviewed. Of the 64 patients, 38 were male individuals and 26 were female individuals, with a male/female ratio of 1.46:1. The median age of the patients with NPC was 40 years old (range: 25--49 years old). All patients with NPC were staged by the 7th edition of the American Joint Committee on Cancer staging system (Pan et al., 2015). Twelve patients (18.75%) were defined as having stage I--II cancer, and the remaining 52 patients (81.25%) were defined as having stage III--IVB cancer. The control group was composed of 31 healthy volunteers. Subjects with a history of diabetes mellitus, hypertension, coronary artery disease, or infectious disease were excluded. Of the 31 healthy individuals, 13 were males and 18 were females, with a male/female ratio of 1:1.38. The median age of the controls was 40 years old (range: 26--57 years old).

Flow cytometry {#sec2-2}
--------------

Peripheral blood samples were obtained and analyzed while still fresh (within 30 min of collection). Flow cytometry was employed to analyze the proportion of immune cells in the peripheral blood of NPC patients and healthy controls. Blood samples (50 μL each) were aliquoted into 11 tubes. Then, 10 μL of fluorescein isothiocyanate-, allophycocyanin-, or phycoerythrin-conjugated mouse monoclonal antibodies (MAbs) to CD3 (Clone UCHT1), CD4 (Clone RPA-T4), CD8 (Clone RPA-T8), CD56 (Clone NCAM 16.2), CD158b (Clone CH-L), NKp30 (Clone p30-15), NKp44 (Clone p44-8), NKp46 (Clone 9E2, also known as 9-E2), and NKG2D (Clone 1D11) from BD Biosciences Company (San Jose, CA, USA) and phycoerythrin-conjugated anti-human CD159a (NKG2A) from Beckman Coulter Inc. (Brea, CA, USA) were considered as markers of surface receptor for analyses. After incubation for 30 min at 4 °C with the appropriate fluorochrome-conjugated MAb, the cells were washed by three times with phosphate-buffered saline solution. Triple- or quadruple-color flow cytometry was conducted on a FACSCalibur instrument (Becton Dickinson, San Jose, CA, USA). Statistical data were obtained and counted with Cell Quest software.

Statistical analysis {#sec2-3}
--------------------

The analyses were all conducted by using SPSS for Windows, version 17.0 (SPSS, Inc., Chicago, IL, USA). The Student's t-test or the nonparametric Mann-Whitney U test was employed to have a comparison among the continuous quantitative parameters. All data were presented as the mean ± standard deviation or median (interquartile range), on the basis of the distribution of different variables. A two-tailed P value of less than 0.05 was deemed to have a statistically significant difference.

Results {#sec1-3}
=======

The proportion of immune cells detected in the peripheral blood between the two groups. When the percentages of immune cells between the NPC patients and the healthy controls were compared by flow cytometry, no statistically significant differences were found in terms of the proportion of NK cells, NKT cells, CD3+ T cells, CD4+ T cells, or CD8+ T cells (all P \> 0.05), as displayed in [Table 1](#T1){ref-type="table"}.

###### 

NK Cells, NKT Cells and T Lymphocytes

                           Patients group   Healthy controls   P^[a](#t1f1){ref-type="table-fn"}^
  ------------------------ ---------------- ------------------ ------------------------------------
  NK lymphocytes(%)        18.67±11.07      15.06±8.77         0.116
  NKT lyphocytes (%)       4.51±2.84        5.53±3.24          0.119
  CD3+ T lymphocytes (%)   69.93±11.64      71.30±8.97         0.563
  CD4+ T lymphocytes (%)   36.35±9.94       36.67±6.45         0.851
  CD8+ T lymphocytes (%)   27.50±10.37      27.90±7.27         0.847

Student's t-test, two sided P.value\<0.05

The expression of certain surface receptors on NK cells. To further analyze the activities of NK cells, some receptors on NK cells were also tested by flow cytometry. From [Table 2](#T2){ref-type="table"}, With regard to the inhibitory receptors on NK cells, no significant differences existed in terms of the percentages of CD158b and CD159a between the patients and the controls. As for the activating receptors on NK cells, the percentage of NKp44 was also not found to be statistically significant. However, the expression levels of NKp30 and NKp46 on NK cells in the NPC patients were shown to be markedly lower than in the healthy controls, with P values of 0.018 and \<0.001, respectively ([Figure 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}).

###### 

The Percentage of Receptors Expressed on NK Cells

                                          Patients group   Healthy controls   P
  --------------------------------------- ---------------- ------------------ ------------------------------------------
  CD158b                                  45.68±21.24      42.08±18.91        0.424^[a](#t2f1){ref-type="table-fn"}^
  CD159a                                  28.27±19.10      31.54±14.07        0.399^[a](#t2f1){ref-type="table-fn"}^
  NKp30[\*](#t2f3){ref-type="table-fn"}   49.81±20.78      60.31±17.77        0.018^[a](#t2f1){ref-type="table-fn"}^
  NKp44                                   1.0 (0.1)        0.3 (0.1)          0.081^[b](#t2f3){ref-type="table-fn"}^
  NKp46[\*](#t2f3){ref-type="table-fn"}   44.21±21.53      60.57±17.71        \<0.001^[a](#t2f1){ref-type="table-fn"}^

Student's t-test;

Mann-Whitney U test;

According to Student's t-test; the value of P \<0.05 indicates statistical significant.

![A Comparison of the Expression Level of NKp30 on NK Cells Between NPC Patients and Healthy Controls by Flow Cytometry. The expression level of NKp30 was significantly lower in 64 NPC peripheral blood samples as compared to that in 31 healthy peripheral blood samples (\* P \<0.05).](APJCP-19-661-g001){#F1}

![A Comparison of the Expression Level of NKp46 on NK Cells Between NPC Patients and Healthy Controls by Flow Cytometry. The expression level of NKp30 was markedly decreased in 64 NPC peripheral blood samples as compared to that in 31 healthy peripheral blood samples (\*\*\* P \<0.001).](APJCP-19-661-g002){#F2}

The expression of NKG2D on immunocytes. NKG2D, a key activating receptor that plays an important role in both innate and adaptive immunity, was expressed not only on NK cells but also on other T lymphocytes. As shown in [Table 3](#T3){ref-type="table"}, no significant differences existed in terms of the expression of NKG2D on NK cells and CD4+ T cells; however, the expression level of NKG2D on CD8+ T lymphocytes in NPC patients was found to be significantly decreased than that of healthy individuals (P \< 0.001) ([Figure 3](#F3){ref-type="fig"}).

###### 

NKG2D Expressed on NK Cells and T Lymphocytes

                                                                    Patients group   Healthy controls   P
  ----------------------------------------------------------------- ---------------- ------------------ ------------------------------------------
  NKG2D on NK cells (%)                                             95.45 (92.83)    96.10 (92.00)      0.877^[b](#t3f2){ref-type="table-fn"}^
  NKG2D on CD4+ T lymphocytes (%)                                   1.05 (0.50)      0.6 (0.4)          0.061^[b](#t3f2){ref-type="table-fn"}^
  NKG2D on CD8+ T lymphocytes (%)[\*](#t3f3){ref-type="table-fn"}   94.14 ± 2.90     96.05 ± 1.96       \<0.001^[a](#t3f1){ref-type="table-fn"}^

Student's t-test;

Mann-Whitney U test;

P \<0.05 indicates statistical significance between the two groups.

![A Comparison of the Expression Level of NKG2D on CD8+ T Lymphocytes Between NPC Patients and Healthy Controls by Flow Cytometry. The expression level of NKG2D on CD8+ T lymphocytes was much lower in 64 NPC peripheral blood samples as compared to that in 31 healthy peripheral blood samples (\*\* P \<0.005).](APJCP-19-661-g003){#F3}

Discussion {#sec1-4}
==========

Over the past several decades, several studies on T lymphocyte dysregulation in the peripheral blood of patients with NPC have shown an association between tumor progression and immunosuppression (Li et al., 2007; Fogg et al., 2013; Chia et al., 2014); however, no research on NK cells and their surface receptors or the expression of NKG2D on immunocytes has been reported to date. Our study represents the first study to investigate the aberrant expression of surface receptors on NK cells and NKG2D on immunocytes in NPC patients, revealing the possible mechanism of tumor escape for NPC. In the present study, our results showed that NPC patients had a lower expression of NKp30, NKp46, and NKG2D on CD8+ T cells than healthy individuals. Therefore, NKp30, NKp46, and NKG2D may be potential biomarkers of immune escape for NPC.

NK cells are known as the first line of defense against infection and tumor cells in the innate immune system; thus, the number of NK cells may increase as a result of activation of innate immunity by the malignant process in NPC (Hu et al., 2012). In our study, however, no statistically notable differences were discovered in the proportion of NK cells between NPC patients and healthy controls, or between NKT cells and certain subsets of T lymphocytes. This finding was in line with the study by Zheng et al., who demonstrated that the frequencies of NK cells were similar between the two groups (Zheng et al., 2006). Thus, we need to investigate further the representative surface receptors on NK cells to evaluate NK cell cytotoxicity.

On further analysis of surface receptors on NK lymphocytes, significantly decreased proportions of NKp30 and NKp46 were observed in NPC patients as compared with the healthy individuals. This finding may suggest that the cytotoxic effect of NK cells was breached due to the decreased expression of NKp30 and NKp46 in NPC patients. NKp30 and NKp46 are both members of the NCR family on NK cells to be correlated with the ability to recognize and lyse transformed and tumor cells (Garcia-Iglesias et al., 2009). NKp30 has been shown to bind to a tumor-specific B7 family homolog (B7-H6) (Brandt et al., 2009) and the nuclear factor HLA-B-associated transcript 3 (BAT3) (Pogge von Strandmann et al., 2007) both can directly trigger NKp30-mediated NK cell cytolytic effects. In addition, heparin sulfate/heparin sequences on cancer cells have been hypothesized to be a type of NKp46-binding motif (Hecht et al., 2009). Hence, the decreased proportions of NKp30 and NKp46 in our study may reveal a mechanism of immunological escape for NPC.

NKG2D is also an important receptor for NK cell activation, but the average percentage of NKG2D was not shown to be statistically different between NPC patients and healthy controls in our study. In fact, NKG2D acts as a costimulatory receptor delivered by many T lymphocytes, such as NKT cells, CD8+ T cells, and certain CD4+ T cells, to increase adaptive immunity activation (11). As expected, our study demonstrated that NKG2D on CD8+ T lymphocytes was markedly decreased in the study group as compared to that in the control group, but no marked difference was found in the proportion of NKG2D on CD4+ T lymphocytes. This finding suggests that the decreased expression of NKG2D on the membrane of CD8+ T cells may weaken the cytotoxic effect of T cells by affecting NKG2D-mediated costimulatory signals. Moreover, tumor cells have been shown to be able to release distinctly soluble ligands of NKG2D into circulating blood to bind to NKG2D, thus inducing the downregulated expression of NKG2D on CD8+ T lymphocytes and impair T cell activation (Lundholm et al., 2014). Therefore, the decreased expression of NKG2D on CD8+ T cells may represent a form of immune evasion in patients with NPC.

The interpretation of the current study was limited by the relatively insufficient number of cases, including only 31 healthy individuals and 64 NPC patients. In addition, other important subpopulations of T lymphocytes such as regulatory T cells and CD44 lymphocytes in NPC patients were not investigated.

In conclusion, our study, for the first time, reported on the downregulation of NKp30, NKp46, and NKG2D on CD8+ T lymphocytes in NPC. These findings may conjecture possible pathways of tumor escape and provide novel therapeutic strategies for NPC in the future.
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